3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Leukemia
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Lung Neoplasms
2
Congenital Abnormalities
2
Thymoma
1
Sarcoma, Ewing
1
Sarcoma
1
Rare Diseases
1
Ovarian Neoplasms
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms, Plasma Cell
1
Neoplasms, Connective and Soft Tissue
1
Neoplasms, Connective Tissue
1
Neoplasms, Bone Tissue
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Mesothelioma
1
Melanoma
1
Lymphoma, Follicular
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Esophageal Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
4
Sunitinib
3
Rituximab
3
Pemetrexed
3
ponatinib
2
pembrolizumab
2
osimertinib
2
Vincristine
2
Prednisone
2
Gemcitabine
2
Etoposide
2
Doxorubicin
2
Cyclophosphamide
2
ricolinostat
1
pralsetinib
1
pomalidomide
1
nilotinib
1
linifanib
1
ibritumomab tiuxetan
1
emvododstat
1
atezolizumab
1
Temozolomide
1
Taxes
1
Sorafenib
1
Papanicolaou Test
1
Paclitaxel
1
Melphalan
1
Irinotecan
1
Interleukin-2
1
Imatinib Mesylate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Neoplasms by Histologic Type
×
FANG vaccine
×
Clear all
NCT03495921
2023-04-26
VITA
Gradalis, Inc.
Phase 3
Terminated
32 enrolled
13 charts